Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Stock data | 2024 | Change |
---|---|---|
Price | $8.06 | N/A |
Market Cap | $353.88M | N/A |
Shares Outstanding | 43.91M | N/A |
Employees | 26.00 | N/A |